Vardenafil hydrochloride trihydrate

Overview

Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 ( PDE5 ), with an IC 50 of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1 , PDE6 with IC 50 s of 180 nM, and 11 nM, while IC 50 s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes [1]-[6] .

Application

Products | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Depression | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Endocrinology | Products > Signaling Pathways > Endogenous Metabolite | Products > Signaling Pathways > Phosphodiesterase (PDE)

Product Information

• Catalog No.: HY-B0442B
• CAS No.: 330808-88-3
• Molecular Formula: C23H39ClN6O7S
• Molecular Weight: 579.11
• Purity: 99.67%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 2.5 mg/mL (4.32 mM); Clear solution
• Availability: In-stock

Source

Original product source